Annex Advisory Services LLC Buys 2,756 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Annex Advisory Services increased its Thermo Fisher stake by 12.6% in the second quarter, purchasing 2,756 shares for a total holding of 24,656 shares valued at approximately $12.36 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported strong quarterly results, with EPS of $6.03 and revenue of $11.99 billion, beating estimates and representing 10.5% year-over-year revenue growth. Analysts maintain a “Moderate Buy” consensus with an average price target of $619.41.
• Recent developments include growth initiatives in India, potential expansion in proteomics and diagnostics, and FDA clearance for a multiple myeloma testing platform. However, insiders sold 26,553 shares worth $15.34 million over the last quarter, including sales by the CEO and vice president under pre-arranged trading plans.

Annex Advisory Services LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 24,656 shares of the medical research company's stock after buying an additional 2,756 shares during the period. Annex Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $12,361,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Assetmark Inc. increased its position in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock worth $21,819,000 after acquiring an additional 7,023 shares during the period. North Dakota State Investment Board bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $7,505,000. Boston Trust Walden Corp grew its position in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock worth $25,480,000 after purchasing an additional 3,873 shares in the last quarter. Xponance LLC raised its position in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock valued at $34,358,000 after buying an additional 4,436 shares in the last quarter. Finally, Merit Financial Group LLC boosted its stake in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company's stock valued at $8,984,000 after buying an additional 3,934 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the business's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. The trade was a 28.35% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 26,553 shares of company stock valued at $15,343,589. 0.33% of the stock is currently owned by company insiders.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher completed Olink Explore HT proteomic analysis of approximately 5,500 samples for The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative. Making the data available to researchers could strengthen adoption of Thermo Fisher’s proteomics platform and support future precision-medicine demand. Thermo Fisher collaborates with The Michael J. Fox Foundation
• Positive Sentiment: A market report projects the non-viral transfection reagents market will grow from $0.89 billion in 2026 to $2.01 billion by 2035, a 9.5% compound annual growth rate. Thermo Fisher’s participation in this market gives investors another potential source of long-term life-sciences growth, though the report does not quantify the company’s expected share. Non-Viral Transfection Reagents Market Report
• Positive Sentiment: Thermo Fisher is targeting 15% to 20% customer-base growth in India over the next five years, supported by expanding biopharmaceutical research and manufacturing. The plan highlights a potentially attractive international growth opportunity for its instruments, services and bioproduction businesses. Thermo Fisher India customer growth
• Positive Sentiment: Recent coverage also highlighted FDA clearance for Thermo Fisher’s multiple myeloma testing platform, potentially broadening its clinical-diagnostics and precision-medicine opportunities among laboratories, hospitals and pharmaceutical companies. Thermo Fisher multiple myeloma platform
• Neutral Sentiment: Coverage of a new vitiligo registry suggests potential benefits for dermatology research and related laboratory workflows, but no specific revenue contribution or commercial agreement was disclosed, limiting the near-term stock impact. New vitiligo registry
• Neutral Sentiment: Articles comparing Thermo Fisher with Danaher, Abbott and Azenta focus on valuation and exposure to a recovery in pharmaceutical and biotechnology research spending rather than announcing new company fundamentals. Thermo Fisher versus Danaher
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares in transactions conducted under pre-arranged Rule 10b5-1 plans. The planned nature reduces the significance, but insider selling can create modest short-term pressure on investor sentiment. Thermo Fisher insider trading filing

Thermo Fisher Scientific Trading Up 0.7%

Shares of TMO stock opened at $604.18 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The stock's fifty day moving average price is $522.21 and its two-hundred day moving average price is $509.48. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market cap of $223.40 billion, a PE ratio of 32.50, a P/E/G ratio of 2.44 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Analyst Upgrades and Downgrades

A number of research firms have commented on TMO. Piper Sandler raised their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research note on Monday, July 27th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday, April 24th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Finally, Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source